COMMUNIQUÉS West-GlobeNewswire

Dr. Myung Ju Lee of VIP Plastic Surgery Receives Minister of Health and Welfare Award at Medical Korea 2026
19/03/2026
National honor recognizes Dr. Lee’s leadership in advancing Korea’s global healthcare standards and excellence in facial plastic surgery SEOUL, Korea, March 19, 2026 (GLOBE NEWSWIRE) -- Myung Ju Lee, MD, PhD, founder of [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
19/03/2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
2026 MAP Awards presented to 20 organizations for high performance in revenue cycle
18/03/2026
CHICAGO, March 18, 2026 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) announced the 2026 winners of the MAP Award for High Performance in Revenue Cycle, including three integrated delivery [...]
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
18/03/2026
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
XOMA Royalty Declares Quarterly Preferred Stock Dividends
18/03/2026
EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and [...]
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
18/03/2026
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth [...]
ADR Ratio Change
18/03/2026
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative [...]
VitalHub Reports Fourth Quarter 2025 Results
18/03/2026
Annual Recurring Revenue (“ARR”)⁽¹⁾ up 35% YoY to $96.1 million Total Revenue up 52% YoY to $31.4 million Adjusted EBITDA⁽¹⁾ up 47% YoY to $7.4 million TORONTO, March 18, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
A supplemental long ‑ form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental [...]
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
18/03/2026
Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 [...]
Extendicare Announces Proposed Changes to Board of Directors
18/03/2026
MARKHAM, Ontario, March 18, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced that its board of directors (“Board of Directors” or “Board”) has nominated Josh Blair [...]
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
18/03/2026
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and [...]
Alvotech Q4 2025 and Full Year 2025 Financial Results
18/03/2026
REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental long ‑ form earnings release providing additional operational [...]
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
18/03/2026
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at [...]
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
18/03/2026
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature Medicine [...]
Ever Joint Claims Evaluated: What the Science Says About EverJoint Joint Support Ingredients
18/03/2026
A 2026 company-issued informational report outlining how Ever Joint positions its joint support formula, ingredient-level research context, oxidative stress claims, pricing structure, and what consumers should verify [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
18/03/2026
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Big Ed's Meds Under Investigation: Safe FDA-Approved ED Medications for Men
18/03/2026
A company-informational report from Big Eds Meds LLC addressing common consumer search questions about the Big Ed's Meds telehealth platform, FDA-approved generic ED medication access, pricing, provider standards, and [...]
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
19/03/2026
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from the OPUS-1 [...]

Pages